Better Choice Acquires Aimia Pet Healthco to Enter the GLP1 Pet Market
- None.
- None.
Insights
The acquisition by Better Choice Company of Aimia Pet Healthco Inc. represents a strategic move to expand its product portfolio in the pet health and wellness sector. With the growing prevalence of pet obesity, which mirrors the human obesity epidemic, there is a clear demand for products that can address this issue. This market trend suggests potential for growth in the sector, as pet owners are increasingly seeking solutions to improve their pets' health and quality of life. The focus on developing supplements for weight loss in domestic animals taps into a niche yet significant segment of the market, which has been previously explored by pharmaceutical giants like Pfizer with Slentrol.
From a market perspective, the success of such products will depend on several factors, including efficacy, safety, cost and consumer acceptance. If Better Choice can successfully develop and market a product that meets these criteria, it could capture a share of the growing market for pet health products, which could, in turn, impact the company's revenue and stock performance positively. However, it is important to consider the competitive landscape, regulatory hurdles and potential challenges in product development and marketing.
From a veterinary standpoint, the development of weight management products for pets is a significant advancement. Obesity in pets can lead to various health complications, including arthritis, diabetes and high blood pressure, which can severely impact their wellbeing and longevity. The integration of Aimia's clinical trial capabilities with Better Choice's product development could potentially lead to innovative solutions that are not only effective but also safe for animal consumption.
It is crucial that any new products undergo rigorous testing to ensure they do not cause adverse effects and that they contribute positively to an animal's diet. The addition of protein and nutrients to promote lean muscle and overall health is an encouraging sign that the products will be formulated with a holistic approach to pet health. This could resonate well with pet owners who are increasingly informed and concerned about the ingredients in their pets' food and supplements.
Financially, the acquisition of Aimia Pet Healthco Inc. by Better Choice Company could be seen as a strategic investment to enhance its R&D capabilities and diversify its product offerings. The pet health and wellness industry is a multi-billion-dollar market with a compound annual growth rate that has been steadily increasing. A successful entry into the pet weight management niche could provide Better Choice with a new revenue stream and potentially increase shareholder value.
Investors will be watching closely for the outcomes of the internal clinical trials and subsequent product launches. The financial implications will depend on the costs associated with R&D, regulatory compliance, marketing and production, as well as the revenue generated from the new products. If Better Choice manages to create a product comparable to human weight loss brands like Wegovy, Ozempic and Mounjaro, it could set a new industry standard. However, investors should be aware of the risks involved in product development, including the possibility of delays or failures in clinical trials, which could impact expected returns.
NEW YORK, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Better Choice Company (NYSE: BTTR) (“Better Choice” or “the Company”), a pet health and wellness company, today announced the acquisition of all the issued and outstanding common shares of Aimia Pet Healthco Inc. (‘Aimia’). Better Choice will now be in a position to manage the clinical trials internally in hopes to develop a supplement to support weight loss in domestic animals.
More than half of all dogs and cats worldwide are classified as overweight or obese and can suffer from the same weight-related health complications as humans – including arthritis, diabetes, and high blood pressure. Following the successful creation by Pfizer of its Slentrol medication, Better Choice will work with Aimia to develop treats and toppers to safely combat pet obesity.
The goal of the research and development work is to mirror the weight loss benefits of leading brands for domestic animals and in humans including Slentrol, Wegovy, Ozempic, and Mounjaro with added protein and nutrients from the Company’s halo products to promote lean muscle and overall pet health.
About Better Choice Company, Inc.
Better Choice Company Inc. is a pet health and wellness company focused on providing pet products and services that help dogs and cats live healthier, happier, and longer lives. We offer a broad portfolio of pet health and wellness products for dogs and cats sold under our Halo brand across multiple forms, including foods, treats, toppers, dental products, chews, and supplements. We have a demonstrated, multi-decade track record of success and are well positioned to benefit from the mainstream trends of growing pet humanization and consumer focus on health and wellness. Our products consist of kibble and canned dog and cat food, freeze-dried raw dog food, and treats, vegan dog food and treats, oral care products and supplements. Halo’s core products are made with high-quality, thoughtfully sourced ingredients for natural, science-based nutrition. Each innovative recipe is formulated with leading veterinary and nutrition experts to deliver optimal health. For more information, please visit https://www.betterchoicecompany.com .
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. The Company has based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Some or all of the results anticipated by these forward-looking statements may not be achieved. Further information on the Company’s risk factors is contained in our filings with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
Investor Contact:
KCSA Strategic Communications
Valter Pinto, Managing Director
T: 212-896-1254
Valter@KCSA.com
FAQ
What did Better Choice Company announce?
What is the goal of the research and development work?
How many dogs and cats worldwide are classified as overweight or obese?
Which medication created by Pfizer is referenced in the press release?
What products will be used to promote lean muscle and overall pet health?
